PetMed Express (PETS) Expected to Announce Earnings on Tuesday

PetMed Express (NASDAQ:PETS) is anticipated to announce its Q2 2027 results after the market closes on Tuesday, November 10th. Analysts expect PetMed Express to announce earnings of ($0.11) per share and revenue of $62.00 million for the quarter. Interested persons can check the company’s upcoming Q2 2027 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

PetMed Express (NASDAQ:PETS) last announced its earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.40). PetMed Express had a negative net margin of 17.34% and a negative return on equity of 91.69%. The firm had revenue of $41.02 million during the quarter, compared to analysts’ expectations of $71.00 million. On average, analysts expect PetMed Express to post ($0.50) EPS for the current fiscal year and ($0.35) EPS for the next fiscal year.

PetMed Express Stock Down 0.4%

NASDAQ PETS traded down $0.01 during trading hours on Tuesday, hitting $1.20. 5,082 shares of the company were exchanged, compared to its average volume of 282,240. The company has a 50 day moving average of $1.47 and a two-hundred day moving average of $2.11. PetMed Express has a 52-week low of $1.15 and a 52-week high of $4.10. The firm has a market cap of $25.91 million, a price-to-earnings ratio of -0.87 and a beta of 0.82.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wall Street Zen cut shares of PetMed Express from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings raised shares of PetMed Express from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 14th. Morgan Stanley decreased their target price on shares of PetMed Express from $2.15 to $1.40 and set an “underweight” rating for the company in a research note on Friday, September 25th. Finally, Zacks Research cut PetMed Express from a “hold” rating to a “strong sell” rating in a research report on Friday, September 25th. Three equities research analysts have rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has an average rating of “Strong Sell” and an average price target of $1.40.

PetMed Express Company Profile

PetMed Express, Inc, doing business as PetMeds, is an online retailer of prescription and nonprescription medications and health products for dogs, cats and other household pets. The company offers products used to treat or prevent conditions such as allergies, infections, parasites and chronic illnesses, including prescription medicines, flea and tick treatments, heartworm preventatives, supplements and other animal-health products.

In addition to medications, PetMeds sells pet food, treats, vitamins, wellness products and selected supplies.